key: cord-0682624-iuohja6w
authors: Zayed, Sondos; Chen, Hanbo; Ali, Emma; Rodrigues, George B.; Warner, Andrew; Palma, David A.; Louie, Alexander V.
title: Is there a Role for Hypofractionated Thoracic Radiotherapy in Limited-Stage Small Cell Lung Cancer? A Propensity Score Matched Analysis
date: 2020-06-13
journal: Int J Radiat Oncol Biol Phys
DOI: 10.1016/j.ijrobp.2020.06.008
sha: 6f24c66bd5a1ffc5a47ae2b9e90806abbdedf839
doc_id: 682624
cord_uid: iuohja6w

ABSTRACT Introduction Various radiation schedules are used in concurrent chemoradiotherapy for limited-stage small cell lung cancer (LS-SCLC). As there is currently no randomized evidence comparing hypofractionated (HFRT) and conventionally-fractionated radiotherapy (CFRT), the aim of this study was to compare overall survival (OS), progression-free survival (PFS), and toxicity of HFRT and CFRT in LS-SCLC. Methods LS-SCLC patients treated between 2000-2013 with HFRT (40Gy/15, 45Gy/15, 45Gy/20 fractions) or CFRT (60Gy/30 or 66Gy/33 fractions) were included. Propensity scores were generated using a multivariable logistic regression model. Patients were matched on a 1:1 ratio with a caliper distance of 0.20. OS and PFS were estimated by the Kaplan-Meier method and compared using log-rank tests. As a sensitivity analysis, univariable and multivariable Cox regression was performed including all patients without matching. Logistic regression was performed to identify predictors of pulmonary and esophageal adverse events. Results In the overall group of 117 patients, there were significant baseline differences between the HFRT and CFRT cohorts. Patients who received CFRT were older, smoked more often concurrently with treatment, had higher ECOG performance status, different T and N stage patterns, and more commonly received concurrent chemoradiotherapy and prophylactic cranial irradiation. After propensity score matching for these differences, 72 patients were included, 36 in the HFRT and CFRT cohorts respectively. There was no difference in OS (P=0.724), PFS (P=0.862), any pulmonary (P=0.350), or esophageal (P=0.097) adverse events between cohorts. Skin adverse events were significantly higher for CFRT (41.7%) compared with HFRT (16.7%, P=0.020). Multivariable Cox regression also revealed no differences in OS (P=0.886) or PFS (P=0.717) between all HFRT and CFRT patients, without matching. No grade 5 adverse events were observed. Conclusion In LS-SCLC patients, HFRT was associated with comparable survival and toxicity outcomes and may be considered as an alternative to CFRT, should its efficacy be confirmed in prospective studies.

Thoracic radiotherapy plays an important role in the management of limited-stage small cell lung cancer (LS-SCLC). 1, 2 Compared to chemotherapy alone, concurrent chemoradiotherapy (CRT) results in improved overall survival (OS). 1,3-7 A variety of radiotherapy dose fractionation regimens are commonly used in CRT for LS-SCLC. 4, 5, [8] [9] [10] [11] [12] [13] [14] [15] Phase III clinical trial data support the use of both hyperfractionated radiotherapy (45 Gy in 30 twice-daily fractions) and high-dose conventionallyfractionated radiotherapy (CFRT, 66 Gy in 33 daily fractions), as these regimens appear to achieve comparable survival outcomes with similar toxicity profiles. 5, 16 Alternatively, hypofractionated radiotherapy (HFRT) using ≥ 2.1 Gy per fraction, is also practiced in certain parts of the world, with a common regimen being 40 Gy in 15 fractions. 15 A phase II trial comparing HFRT to hyperfractionated radiotherapy demonstrated similar progression-free and overall survival outcomes, although this study had a limited sample size, restricting its power. 17 There is currently no completed randomized clinical trial comparing HFRT to CFRT, yet HFRT remains the preferred radiotherapy schedule in several countries. 15 HFRT may be preferred over CFRT or hyperfractionation due to a shorter overall treatment time, decreased resource utilization, and patient convenience with single daily visits. 18 In the absence of randomized evidence, non-randomized evidence can be used judiciously after controlling for confounding factors that contribute to selection bias. Propensity score methods can attain more stable estimates of comparative effectiveness in the setting of a low ratio of outcome events to potential confounders. 19 Therefore, the objective of this study was to compare the survival outcomes and toxicities of HFRT with CFRT using propensity score-matched retrospective data.

We retrospectively analyzed LS-SCLC patients treated with either HFRT or CFRT between January 2000 and December 2013, identified from an institutional database at the XXXX. Patients who had extrathoracic metastases were excluded with the exception of those with ipsilateral supraclavicular lymphadenopathy, ipsilateral malignant pleural effusion, or contralateral mediastinal lymphadenopathy, which could be encompassed within the same radiation field. HFRT was defined as ≥ 2.1 Gy per fraction and a total dose between 37 and 50 Gy. CFRT was defined as 2 Gy per fraction, with ≥ 29 fractions, and a total dose ≥ 58 Gy. The institutional ethics review board approved the study (project ID: 105398).

Propensity scores were generated using multivariable logistic regression models predictive of treatment assignment (HFRT or CFRT). Matching was performed on age, concurrent smoking with treatment, Eastern Cooperative Oncology Group (ECOG) performance status (0-1 vs. 2-3), T stage, N stage (AJCC Cancer Staging Manual 6th edition), concurrent CRT, prophylactic cranial irradiation (PCI), central tumor location, and the presence of a pleural effusion. Central tumors were defined according to the International Classification of Diseases (ICD) 9/10 Site Code as those located at or near the main bronchus, carina, or hilus of the lung. 20,21 All possible interaction terms were examined, and no significant interactions were found.

Using the initial sample size (n=117) and a ratio of 1:1, 3 matches were generated. Three scenarios for each match were examined using caliper widths of 0.10, 0.20, and 0.2*(standard deviation)*Logit(Propensity score), respectively. 22-25 The caliper distance of 0.20 was selected as it generated the best final match with no standardized differences ≥ 0.3 in the covariates of interest.

Standardized differences were used to assess balance between treatment groups across variables in the propensity score model. A standardised difference < 0.10 was considered representative of 'negligible imbalance' between treatment groups. 26-28 Only one standardized difference was between 0.2 and 0.3 (T3 stage), and 3 standardized differences were between 0.1 and 0.2 (T4 stage, PCI status, and central tumor location; Supplementary Table A) . The final match was selected before analysis of treatment outcomes.

Descriptive statistics were generated for baseline patient characteristics, stratified by cohort The endpoints of this study included OS, PFS, any pulmonary adverse events (PAE) of any grade, and any esophageal adverse events (EAE) of any grade. OS was calculated as the time from date of diagnosis to date of last follow-up and/or death of any cause, whichever came first. PFS was calculated as time from the date of diagnosis to date of recurrence, date of last follow-up and/or death from any cause, whichever came first.

Both propensity score matching and multivariable modelling can be used to control for confounders. However, since there is no clear consensus on a preferred method 29 , a sensitivity analysis was performed using univariable and multivariable Cox proportional hazards models for OS and PFS for all patients (n=117). We wished to examine whether the reduced power associated with propensity score matching led to different results compared to traditional statistical techniques that may be prone to unstable estimates with a high number of potential confounders. Multivariable Cox regression models were generated by using treatment as the main exposure and adjusting for the potential confounders of age, smoking concurrent with treatment, ECOG performance status, T stage, N stage, concurrent CRT, PCI, central location, and pleural effusion. Violation of the proportional hazards assumption in Cox regression was evaluated using the Kolmogorov-Supremum test. If violations were detected, a timedependent covariate was added to the Cox regression model and a P-value was reported from a likelihood ratio test.

Logistic regression was performed to compare PAE and EAE between CFRT and HFRT cohorts in the matched and unmatched patient groups. For matched comparisons, only univariable models were performed and these models were stratified by matched pair to account for the matched design.

Multivariable logistic regression models in the unmatched cohort were generated for any PAE and any EAE, adjusting for the potential confounders of age, smoking concurrent with treatment, ECOG performance status, T stage, N stage, concurrent chemoradiotherapy, and central location.

All statistical analysis was performed in SAS version 9.4 (SAS Institute, Cary, NC, USA), using twosided statistical testing at the 0.05 significance level.

A total of 117 patients were treated with HFRT or CFRT from 2000 to 2013 at our institution.

Fifty-six received low-dose HFRT and 61 received high-dose CFRT. In the original group of 117 patients, there were significant standardized baseline differences between the CFRT and HFRT cohorts for age, concurrent smoking with treatment, ECOG performance status, T and N stage, concurrent CRT, and PCI. Table 1 .

The median follow-up duration was significantly longer in the HFRT cohort (13.5 years) compared with the CFRT cohort (5.0 years), for all patients (P=0.020), and for matched patients (P=0.001). Baseline treatment outcomes, stratified by cohort, are shown in Table 2 , for all patients and for matched patients.

Kaplan-Meier plots for OS and PFS are displayed in Figure 1B The most common locations for progression in matched HFRT patients were brain (30.6%) then ipsilateral lung (19.4%). For matched CFRT patients, the most common locations for progression were ipsilateral lung (30.6%), lymph nodes (22.2%), brain (19.4%), contralateral lung (16.7%) and bone (13.9%). A significantly higher proportion of matched CFRT patients progressed in the lymph nodes compared with HFRT patients (HFRT: 2.8% vs. CFRT: 22.2%, P=0.028). No other statistically significant differences in patterns of progression were noted between matched cohorts.

Kaplan-Meier plots for OS and PFS are displayed in Figure 1A and 1C, for all patients (n=117), stratified by treatment cohort (HFRT vs. CFRT). Five-year OS was 26.2% for all patients who received HFRT compared with 24.0% for all patients who received CFRT (Supplemental Table B (Table 3) . On univariable analysis only, concurrent CRT was associated with an improvement in PFS (HR: 0.51; 95% CI: 0.27 to 0.97; P=0.039), without a statistically significant OS benefit (HR: 0.53; 95% CI: 0.27 to 1.02; P=0.056). Concurrent smoking during radiotherapy treatment was associated with a reduction in OS (HR: 1.85; 95% CI: 1.10 to 3.13; P=0.021) on multivariable analysis only.

For all patients and for matched patients, no significant differences between cohorts were noted for PAE, EAE, or neutrophil adverse events ( 

Concurrent chemoradiotherapy is the cornerstone of LS-SCLC treatment with various radical radiotherapy fractionation regimens used worldwide. 5 Although twice-daily or standard fractionation is considered standard of care 5, 30 , hypofractionation offers a viable, more convenient alternative which may partly alleviate barriers to access by reducing the total number of fractions and therefore overall treatment time. 31 To our knowledge, this is the first study to use propensity score-matched analysis of retrospective data to compare OS, PFS, and toxicity profiles of HFRT and CFRT in LS-SCLC. We found that there was no statistically significant difference in OS or PFS between HFRT and CFRT in unmatched analysis, propensity score-matched analysis, or univariable and multivariable regression analyses. The pulmonary and esophageal toxicity profile for both CFRT and HFRT was similar for all patients and for matched patients on univariable logistic regression model analysis and for unmatched patients on multivariable logistic regression model analysis. Neutrophil toxicity is most likely attributed to chemotherapy given that there was no significant difference in neutrophil adverse events between HFRT and CFRT for all and for matched patients respectively. Both treatment approaches therefore have comparable tolerability and toxicity profiles with the exception of a possible increased risk of skin toxicity with the high-dose CFRT regimen. Age, concurrent smoking with treatment, T stage, N stage, concurrent CRT and central location do not appear to be predictors of either pulmonary or esophageal adverse events.

The recent ASTRO SCLC clinical practice guideline indicates that mild hypofractionation is not routinely recommended for ES-SCLC due to limited evidence for its equivalence. 30 However, reducing overall treatment time is important for patients who may struggle with prolonged treatment courses, a challenge further amplified by the current COVID-19 viral pandemic. Advantages of hypofractionation thus include patient convenience and reduction in healthcare resource utilization, without compromising clinical efficacy, according to the present study. 32 These findings will need to be verified with more thorough prospective studies, which should also focus on early as well as late toxicities. An increasingly appreciated late effect of thoracic radiotherapy is cardiotoxicity, which warrants further examination in the context of different fractionation regimens. It has been shown that a short time between the start of any treatment to end of radiotherapy (SER) is the most important predictor of outcome in LS-SCLC patients. 37 PCI has been shown to improve both OS and disease-free survival among patients with SCLC. [38] [39] [40] This finding has been reproduced in this study: PCI was associated with an increase in OS and PFS (HR of 0.51 and 0.53 respectively), thereby supporting the validity of the data collected and the analysis performed. Similarly, concurrent CRT was associated with an improvement in PFS, as in previous studies, 1,7 but did not reach statistical significance for OS. We also observed that in patients undergoing concurrent CRT, CFRT was associated with fewer total cycles of chemotherapy delivered (median 5 vs. 6

cycles) compared to those treated with HFRT. Given the retrospective nature of the present study, it is difficult to ascertain the reason for this difference. Possible explanations include that the overall lengthier treatment time of CFRT resulted in difficulty tolerating subsequent cycles of chemotherapy, or alternatively, fewer cycles of chemotherapy were felt to be required with CFRT. Concurrent smoking with radiotherapy treatment was associated with a reduction in OS (HR=1.85), suggesting that clinicians should counsel their patients on smoking cessation and enroll them in smoking cessation programs. 41, 42 In our study, the median year of diagnosis for patients who received HFRT was 2002 whereas the median year of diagnosis for those who received CFRT was 2010. CFRT is a more modern treatment approach, planned and delivered using more contemporary techniques. As a result, 82.0% of CFRT was delivered using intensity-modulated radiation therapy (IMRT), compared with only 5.4% of HFRT cases.

Similarly, 4D planning, which manages respiration during imaging and planning of radiotherapy, was used in only 14.3% of HFRT cases compared with 90.2% of CFRT cases ( Additionally, using the entire cohort in our multivariable Cox regression sensitivity analysis did not significantly change our estimates or conclusions. The retrospective, observational nature of the data collected may have introduced bias. However, differences in baseline characteristics have been accounted for using propensity score matching and confirmed using multivariable regression. Although comparative effectiveness methods such as propensity score matching bring us closer to a balanced comparison of cohorts, they do not completely remove bias due to the potential presence of unmeasured confounders. Lower grades of toxicity could not be reliably distinguished based on chart information, therefore requiring pooling of the data for grade 1 to 3 adverse events. It has been suggested that concurrent CRT confers an OS benefit for elderly patients (age ≥ 70 years). 44 However, no meaningful conclusions specific to the elderly could be drawn in this study due to an insufficient number of elderly patients in the database. It is therefore unknown whether elderly patients would benefit more from HFRT or CFRT in the form of OS, PFS, or reduced toxicity. Finally, long-term complications were outside the scope of the institutional database and were not assessed by the current study.

In LS-SCLC patients, there appeared to be no significant differences in OS, PFS, or toxicity between the HFRT and CFRT treatment approaches with concurrent chemotherapy. CFRT may be associated with higher rates of skin toxicity. HFRT may therefore be considered an effective and comparably tolerable treatment alternative to CFRT, with the added potential benefit of reduced treatment time and cost. Prospective studies are nevertheless required to confirm the comparative role of HFRT to other more common fractionation regimens for the key endpoints of OS, PFS, and toxicity. 

A meta-analysis of thoracic radiotherapy for small-cell lung cancer

Role of thoracic radiotherapy in limited-stage small-cell lung cancer: quantitative review based on the literature versus meta-analysis based on individual data

Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group

Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an openlabel, phase 3, randomised, superiority trial

70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808

Limited-stage small-cell lung cancer (stages I-III): observations from the National Cancer Data Base

The CONVERT Trial: Interpretation, Journey and Lessons Learnt

Long-term results of a phase III trial comparing oncedaily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer

Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53)

Phase 2 study of accelerated hypofractionated thoracic radiation therapy and concurrent chemotherapy in patients with limited-stage small-cell lung cancer

Phase I dose escalation trial of hypofractionated limited-field external beam thoracic radiotherapy for limited-stage small cell carcinoma of the lung

Phase I study of hypofractionated dose-escalated thoracic radiotherapy for limited-stage small-cell lung cancer

A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904

Management of small-cell lung cancer with radiotherapy-a pan-Canadian survey of radiation oncologists

A retrospective analysis of survival outcomes for two different radiotherapy fractionation schedules given in the same overall time for limited stage small cell lung cancer

Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer

Prophylactic cranial irradiation for patients with smallcell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group

Patterns of failure after prophylactic cranial irradiation in small-cell lung cancer: analysis of 505 randomized patients

Prophylactic cranial irradiation in extensive small-cell lung cancer

The effect of cigarette smoking on cancer treatment-related side effects

Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival

18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review

Role of Chemoradiotherapy in Elderly Patients With Limited-Stage Small-Cell Lung Cancer

 HFRT